Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
AssigneeNorthwest Biotherapeutics, Inc.
InventorsGerald P. Murphy, Alton L. Boynton, Anil Sehgal
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicant's surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.
Claims10
A method of inhibiting the proliferation of a cell within a brain tumor, neuroblastoma or breast tumor that over-expresses SDF-1 (SEQ ID NO:
- 4) in a subject comprising administering to the subject in which such treatment is desired a therapeutically effective amount of an antibody that specifically binds to SDF-1 (SEQ ID NO:4) and that inhibits SDF-1 binding to CXCR-4 on the tumor cell.
Dependencies are inferred from the claim text.